Cancer Q&A with HOA: Helping with Cancer Journey and Survivorship

Cancer Q&A with HOA: May is Clinical Trials Awareness Month

Colorectal, Pfizer C6461003

ClinicalTrials.gov ID: NCT07222800

An interventional, phase III, double-blinded, randomized study to evaluate the efficacy and safety of PF-08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatment-naïve participants with metastatic colorectal cancer.

Cancer Q&A with HOA: Esophageal Cancer with Dr. Santosh Kumar

Prostate, 20230239 “XALience”

ClinicalTrials.gov ID:  NCT07213674

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

Cancer Q&A with HOA: March is Multiple Myeloma Awareness Month

Cancer Q&A with HOA: Receiving Clarity Through Second Opinions

Urothelial, S1937

ClinicalTrials.gov ID: NCT04579224

Prostate, Viper, URCC 22053

ClinicalTrials.gov ID: NCT05838716

Lung, Merck V940 INTerpath-009

ClinicalTrials.gov ID: NCT06623422

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy.

Pages